Latest Pharma Insights
Chinese AI-Driven Drug Developers Rake In VC/PE Funds
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
Estée Lauder Pays Fine For Violating Canadian Law Over Cosmetic PFAS
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
New York Congressional Delegation Member Slams State’s Age-Restricted Supplement Sales Law
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
Chinese AI-Driven Drug Developers Rake In VC/PE Funds
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.
Scrip - February 5, 2026
US FDA’s Failure To Implement Key Workforce Reforms Puts Oversight At Risk, GAO Says
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
Medtech Insight - February 4, 2026
Recommendations to mitigate attrition among clinical research and drug manufacturing investigators at the FDA have not been implemented, and a Strategic Workforce Plan aimed at addressing recruiting, retention and training challenges has been shelved, the Government Accountability Office said.
Medtech Insight - February 4, 2026
Lower US Tariffs Open Export Window For Indian Devices As Manufacturing Looks Away From China
The timing of the US tariff reset is also notable. It comes days after India and the European Union concluded a trade deal under which duties on medical devices will be cut from 27% to zero, while allowing liberalized tariffs for devices made in India.
Medtech Insight - February 4, 2026
The timing of the US tariff reset is also notable. It comes days after India and the European Union concluded a trade deal under which duties on medical devices will be cut from 27% to zero, while allowing liberalized tariffs for devices made in India.
Medtech Insight - February 4, 2026
More Accuracy Issues For Magellan Diagnostics Blood Lead Tests
The US FDA has warned that Magellan Diagnostics blood lead tests may provide inaccurately high results, particularly with tubes from ASP Global. Magellan’s tests had previously been recalled over inaccurate low results. The FDA also issued warning letters to both firms.
Medtech Insight - February 4, 2026
The US FDA has warned that Magellan Diagnostics blood lead tests may provide inaccurately high results, particularly with tubes from ASP Global. Magellan’s tests had previously been recalled over inaccurate low results. The FDA also issued warning letters to both firms.
Medtech Insight - February 4, 2026
Stryker Taps ASCs With Mako RPS As Mako 4 Drives Record Robot Installations
Stryker’s broader orthopedics portfolio continued to benefit from strong robotic demand during the quarter, with the company reporting 28.7% organic growth in its US Orthopedics other than hips and knees business.
Medtech Insight - February 4, 2026
Stryker’s broader orthopedics portfolio continued to benefit from strong robotic demand during the quarter, with the company reporting 28.7% organic growth in its US Orthopedics other than hips and knees business.
Medtech Insight - February 4, 2026
Medtronic To Acquire Cathworks For $585M, Expanding Its Cardiology Portfolio
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
Medtech Insight - February 4, 2026
Medtronic has agreed to acquire Cathworks for up to $585m, converting a long-standing partnership into full ownership as it expands its footprint in coronary physiology and AI-enabled cardiovascular tools.
Medtech Insight - February 4, 2026
Estée Lauder Pays Fine For Violating Canadian Law Over Cosmetic PFAS
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
The Estee Lauder Companies, Inc. pleaded guilty to two counts of violating a Canadian Act that had required it to correct missteps related to selling products containing PFAS.
HBW Insight - February 5, 2026
New York Congressional Delegation Member Slams State’s Age-Restricted Supplement Sales Law
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
“Dietary Supplement Regulatory Uniformity Act” would prohibit states from adding requirements and rules for supplement manufacturing and sales on top of FDA regulations.
HBW Insight - February 5, 2026
Bausch And Lannett To Pay Up Nearly $18m In A US Price-Fixing Settlement
With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.
Generics Bulletin - February 4, 2026
With another settlement secured, US states are gearing up for the first trial of the price-fixing case later this year.
Generics Bulletin - February 4, 2026
Sun On ‘Disciplined’ M&A Approach, Day-One Launch Readiness For Semaglutide In India
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin - February 4, 2026
Sun’s founder reinforces the firm’s M&A strategy, indicating that it is "comfortable raising debt" if required, but shares no specific comment on the speculated interest in Organon. The Indian company also has "sufficient supplies" to meet demand for generic semaglutide in India post LoE.
Generics Bulletin - February 4, 2026
‘These Decisions Created A Lot Of Uncertainty’ – Why The Supreme Court’s Skinny-Label Ruling Matters
The US Supreme Court’s decision to review Hikma and Amarin’s litigation over induced infringement of carved-out patented indications offers a chance to resolve key questions around skinny-label generics, according to Chad Landmon, chair of law firm Polsinelli’s Hatch-Waxman & biologics practice.
Generics Bulletin - February 4, 2026
The US Supreme Court’s decision to review Hikma and Amarin’s litigation over induced infringement of carved-out patented indications offers a chance to resolve key questions around skinny-label generics, according to Chad Landmon, chair of law firm Polsinelli’s Hatch-Waxman & biologics practice.
Generics Bulletin - February 4, 2026
Santhera’s DMD Research Is A Labor Of Love
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
In Vivo - February 4, 2026
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
In Vivo - February 4, 2026
Medtech Companies Seek More Device Input Into EU’s Cardiovascular Disease Plan
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
In Vivo - February 4, 2026
Cardiovascular disease is moving to the top of the EU’s health agenda with the release of the Safe Hearts Plan, European Parliament scrutiny of which is expected at the end of Q1. Medical device companies applaud the initiative but will seek more input as the plan evolves.
In Vivo - February 4, 2026
Financing Quarterly Statistics, Q4 2025
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
In Vivo - February 4, 2026
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
In Vivo - February 4, 2026